{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:50:43Z","timestamp":1772164243586,"version":"3.50.1"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"17","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The genetic changes and mechanisms underlying the progression of estrogen-dependent breast cancers to estrogen-independent, antiestrogen-resistant, and metastatic breast cancers are unclear despite being a major problem in endocrine therapy. To identify genes responsible for this progression, we carried out a genetic screening by an enhanced retroviral mutagen (ERM)\u2013mediated random mutagenesis in the estrogen-dependent T47D breast cancer cells. We found that T47D cells contain only one p27kip1 (p27) allele coding for the p27 cyclin-dependent kinase (CDK) inhibitor. An ERM insertion into the p27 locus of T47D cells disrupted the p27 gene and created estrogen-independent and antiestrogen-resistant breast cancer cells that still maintained functional estrogen receptors. Disruption of p27 in T47D cells resulted in several changes, and most of these changes could be rescued by p27 restoration. First, CDK2 activity was increased in the absence of estrogen or in the presence of estrogen antagonists tamoxifen or ICI 182780; second, amplified in breast cancer 1 (AIB1), a cancer overexpressed transcriptional coactivator, was hyperphosphorylated, which made AIB1 a better coactivator for E2F1; and third, growth factor receptor binding protein 2\u2013associated binder 2 (Gab2) and Akt activity were increased following E2F1 overactivation, leading to a significant enhancement of cell migration and invasion. Furthermore, the p27-deficient cells, but not T47D control cells, developed lung metastasis in an ovarian hormone\u2013independent manner when they were i.v. injected into nude mice. In sum, loss of p27 activated AIB1, E2F1, Gab2, and Akt; increased cell migration and invasion; caused antiestrogen insensitivity; and promoted metastasis of breast cancer cells. These findings suggest that p27 plays an essential role in restriction of breast cancer progression. [Cancer Res 2007;67(17):8032\u201342]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-0083","type":"journal-article","created":{"date-parts":[[2007,9,5]],"date-time":"2007-09-05T14:53:07Z","timestamp":1189003987000},"page":"8032-8042","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Genetic Screening Reveals an Essential Role of p27kip1 in Restriction of Breast Cancer Progression"],"prefix":"10.1158","volume":"67","author":[{"given":"Yuhui","family":"Yuan","sequence":"first","affiliation":[{"name":"1Molecular and Cellular Biology and Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Qin","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Biology and Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[{"name":"2Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray-Chang","family":"Wu","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Biology and Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Mussi","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Biology and Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suoling","family":"Zhou","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Biology and Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Songyang","sequence":"additional","affiliation":[{"name":"2Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Xu","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Biology and Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2007,9,5]]},"reference":[{"key":"2022061623242624600_B1","doi-asserted-by":"crossref","unstructured":"Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer\u20082003; 10: 179\u201386.","DOI":"10.1677\/erc.0.0100179"},{"key":"2022061623242624600_B2","doi-asserted-by":"crossref","unstructured":"Foster JS, Fernando RI, Ishida N, Nakayama KI, Wimalasena J. Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem\u20082003; 278: 41355\u201366.","DOI":"10.1074\/jbc.M302830200"},{"key":"2022061623242624600_B3","doi-asserted-by":"crossref","unstructured":"Jordan VC. Third annual William L. McGuire Memorial Lecture. \u201cStudies on the estrogen receptor in breast cancer\u201d-20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat\u20081995; 36: 267\u201385.","DOI":"10.1007\/BF00713399"},{"key":"2022061623242624600_B4","unstructured":"Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res\u20082003; 9 Pt 2: 447\u201354S."},{"key":"2022061623242624600_B5","doi-asserted-by":"crossref","unstructured":"Brodie A. Aromatase inhibitor development and hormone therapy: a perspective. Semin Oncol\u20082003; 30: 12\u201322.","DOI":"10.1016\/S0093-7754(03)00303-8"},{"key":"2022061623242624600_B6","doi-asserted-by":"crossref","unstructured":"Robertson JF. Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer\u20081996; 73: 5\u201312.","DOI":"10.1038\/bjc.1996.2"},{"key":"2022061623242624600_B7","doi-asserted-by":"crossref","unstructured":"Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer. Oncology\u20082001; 61 Suppl 2: 73\u201382.","DOI":"10.1159\/000055405"},{"key":"2022061623242624600_B8","doi-asserted-by":"crossref","unstructured":"Lupu R, Cardillo M, Cho C, et al. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat\u20081996; 38: 57\u201366.","DOI":"10.1007\/BF01803784"},{"key":"2022061623242624600_B9","doi-asserted-by":"crossref","unstructured":"Lobenhofer EK, Huper G, Iglehart JD, Marks JR. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ\u20082000; 11: 99\u2013110.","DOI":"10.1016\/S0960-0760(00)00132-1"},{"key":"2022061623242624600_B10","unstructured":"Tsai EM, Wang SC, Lee JN, Hung MC. Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res\u20082001; 61: 8390\u20132."},{"key":"2022061623242624600_B11","unstructured":"Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. ErbB2\/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res\u20082001; 61: 6583\u201391."},{"key":"2022061623242624600_B12","doi-asserted-by":"crossref","unstructured":"Yang HY, Shao R, Hung MC, Lee MH. p27 Kip1 inhibits HER2\/neu-mediated cell growth and tumorigenesis. Oncogene\u20082001; 20: 3695\u2013702.","DOI":"10.1038\/sj.onc.1204472"},{"key":"2022061623242624600_B13","doi-asserted-by":"crossref","unstructured":"Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB\/Akt-mediated phosphorylation in breast cancer. Nat Med\u20082002; 8: 1136\u201344.","DOI":"10.1038\/nm762"},{"key":"2022061623242624600_B14","doi-asserted-by":"crossref","unstructured":"Liang J, Zubovitz J, Petrocelli T, et al. PKB\/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med\u20082002; 8: 1153\u201360.","DOI":"10.1038\/nm761"},{"key":"2022061623242624600_B15","doi-asserted-by":"crossref","unstructured":"Shin I, Yakes FM, Rojo F, et al. PKB\/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med\u20082002; 8: 1145\u201352.","DOI":"10.1038\/nm759"},{"key":"2022061623242624600_B16","doi-asserted-by":"crossref","unstructured":"Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol\u20082003; 13: 41\u20137.","DOI":"10.1016\/S1044-579X(02)00098-6"},{"key":"2022061623242624600_B17","doi-asserted-by":"crossref","unstructured":"Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med\u20081997; 3: 227\u201330.","DOI":"10.1038\/nm0297-227"},{"key":"2022061623242624600_B18","doi-asserted-by":"crossref","unstructured":"Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1\/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A\u20082000; 97: 9042\u20136.","DOI":"10.1073\/pnas.160016897"},{"key":"2022061623242624600_B19","doi-asserted-by":"crossref","unstructured":"Donovan JC, Milic A, Slingerland JM. Constitutive MEK\/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem\u20082001; 276: 40888\u201395.","DOI":"10.1074\/jbc.M106448200"},{"key":"2022061623242624600_B20","doi-asserted-by":"crossref","unstructured":"Hwang HC, Martins CP, Bronkhorst Y, et al. Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis. Proc Natl Acad Sci U S A\u20082002; 99: 11293\u20138.","DOI":"10.1073\/pnas.162356099"},{"key":"2022061623242624600_B21","doi-asserted-by":"crossref","unstructured":"Musgrove EA, Davison EA, Ormandy CJ. Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice. J Mammary Gland Biol Neoplasia\u20082004; 9: 55\u201366.","DOI":"10.1023\/B:JOMG.0000023588.55733.84"},{"key":"2022061623242624600_B22","doi-asserted-by":"crossref","unstructured":"Louie MC, Zou JX, Rabinovich A, Chen HW. ACTR\/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol\u20082004; 24: 5157\u201371.","DOI":"10.1128\/MCB.24.12.5157-5171.2004"},{"key":"2022061623242624600_B23","doi-asserted-by":"crossref","unstructured":"Mussi P, Yu C, O'Malley BW, Xu J. Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol Endocrinol\u20082006; 20: 3105\u201319.","DOI":"10.1210\/me.2005-0522"},{"key":"2022061623242624600_B24","doi-asserted-by":"crossref","unstructured":"Xu J, Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol\u20082003; 17: 1681\u201392.","DOI":"10.1210\/me.2003-0116"},{"key":"2022061623242624600_B25","doi-asserted-by":"crossref","unstructured":"Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science\u20081997; 277: 965\u20138.","DOI":"10.1126\/science.277.5328.965"},{"key":"2022061623242624600_B26","doi-asserted-by":"crossref","unstructured":"Torres-Arzayus MI, De Mora JF, Yuan J, et al. High tumor incidence and activation of the PI3K\/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell\u20082004; 6: 263\u201374.","DOI":"10.1016\/j.ccr.2004.06.027"},{"key":"2022061623242624600_B27","doi-asserted-by":"crossref","unstructured":"Kuang SQ, Liao L, Wang S, Medina D, O'Malley BW, Xu J. Mice lacking the amplified in breast cancer 1\/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis. Cancer Res\u20082005; 65: 7993\u20138002.","DOI":"10.1158\/0008-5472.CAN-05-1179"},{"key":"2022061623242624600_B28","doi-asserted-by":"crossref","unstructured":"Kuang SQ, Liao L, Zhang H, Lee AV, O'Malley BW, Xu J. AIB1\/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res\u20082004; 64: 1875\u201385.","DOI":"10.1158\/0008-5472.CAN-03-3745"},{"key":"2022061623242624600_B29","doi-asserted-by":"crossref","unstructured":"Wu RC, Qin J, Yi P, et al. Selective phosphorylations of the SRC-3\/AIB1 coactivator integrate genomic responses to multiple cellular signaling pathways. Mol Cell\u20082004; 15: 937\u201349.","DOI":"10.1016\/j.molcel.2004.08.019"},{"key":"2022061623242624600_B30","doi-asserted-by":"crossref","unstructured":"Chaussepied M, Ginsberg D. Transcriptional regulation of AKT activation by E2F. Mol Cell\u20082004; 16: 831\u20137.","DOI":"10.1016\/j.molcel.2004.11.003"},{"key":"2022061623242624600_B31","doi-asserted-by":"crossref","unstructured":"Chau NM, Ashcroft M. Akt2: a role in breast cancer metastasis. Breast Cancer Res\u20082004; 6: 55\u20137.","DOI":"10.1186\/bcr739"},{"key":"2022061623242624600_B32","doi-asserted-by":"crossref","unstructured":"Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer\u20082002; 2: 489\u2013501.","DOI":"10.1038\/nrc839"},{"key":"2022061623242624600_B33","doi-asserted-by":"crossref","unstructured":"Liu D, Yang X, Yang D, Songyang Z. Genetic screens in mammalian cells by enhanced retroviral mutagens. Oncogene\u20082000; 19: 5964\u201372.","DOI":"10.1038\/sj.onc.1203992"},{"key":"2022061623242624600_B34","doi-asserted-by":"crossref","unstructured":"Musgrove EA, Hunter LJ, Lee CS, Swarbrick A, Hui R, Sutherland RL. Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2. J Biol Chem\u20082001; 276: 47675\u201383.","DOI":"10.1074\/jbc.M106371200"},{"key":"2022061623242624600_B35","doi-asserted-by":"crossref","unstructured":"Sartorius CA, Shen T, Horwitz KB. Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Res Treat\u20082003; 79: 287\u201399.","DOI":"10.1023\/A:1024031731269"},{"key":"2022061623242624600_B36","doi-asserted-by":"crossref","unstructured":"Oh A, List HJ, Reiter R, et al. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res\u20082004; 64: 8299\u2013308.","DOI":"10.1158\/0008-5472.CAN-04-0354"},{"key":"2022061623242624600_B37","doi-asserted-by":"crossref","unstructured":"Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer. J Natl Cancer Inst\u20082004; 96: 926\u201335.","DOI":"10.1093\/jnci\/djh166"},{"key":"2022061623242624600_B38","doi-asserted-by":"crossref","unstructured":"Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J\u20081996; 15: 6541\u201351.","DOI":"10.1002\/j.1460-2075.1996.tb01045.x"},{"key":"2022061623242624600_B39","doi-asserted-by":"crossref","unstructured":"Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature\u20081995; 378: 785\u20139.","DOI":"10.1038\/378785a0"},{"key":"2022061623242624600_B40","doi-asserted-by":"crossref","unstructured":"Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol\u20082005; 17: 499\u2013508.","DOI":"10.1016\/j.ceb.2005.08.014"},{"key":"2022061623242624600_B41","doi-asserted-by":"crossref","unstructured":"Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol\u20082003; 169: 1122\u201333.","DOI":"10.1097\/01.ju.0000051580.89109.4b"},{"key":"2022061623242624600_B42","doi-asserted-by":"crossref","unstructured":"Wang Z, Rose DW, Hermanson O, et al. Regulation of somatic growth by the p160 coactivator p\/CIP. Proc Natl Acad Sci U S A\u20082000; 97: 13549\u201354.","DOI":"10.1073\/pnas.260463097"},{"key":"2022061623242624600_B43","doi-asserted-by":"crossref","unstructured":"Wu FY, Wang SE, Sanders ME, et al. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res\u20082006; 66: 2162\u201372.","DOI":"10.1158\/0008-5472.CAN-05-3304"},{"key":"2022061623242624600_B44","doi-asserted-by":"crossref","unstructured":"Goukassian D, Diez-Juan A, Asahara T, et al. Overexpression of p27(Kip1) by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis. FASEB J\u20082001; 15: 1877\u201385.","DOI":"10.1096\/fj.01-0065com"},{"key":"2022061623242624600_B45","doi-asserted-by":"crossref","unstructured":"McAllister SS, Becker-Hapak M, Pintucci G, Pagano M, Dowdy SF. Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol\u20082003; 23: 216\u201328.","DOI":"10.1128\/MCB.23.1.216-228.2003"},{"key":"2022061623242624600_B46","doi-asserted-by":"crossref","unstructured":"Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation\u20082001; 103: 2967\u201372.","DOI":"10.1161\/01.CIR.103.24.2967"},{"key":"2022061623242624600_B47","doi-asserted-by":"crossref","unstructured":"Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev\u20082004; 18: 862\u201376.","DOI":"10.1101\/gad.1185504"},{"key":"2022061623242624600_B48","doi-asserted-by":"crossref","unstructured":"Baldassarre G, Belletti B, Nicoloso MS, et al. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell\u20082005; 7: 51\u201363.","DOI":"10.1016\/j.ccr.2004.11.025"},{"key":"2022061623242624600_B49","doi-asserted-by":"crossref","unstructured":"Gao Y, Kitagawa K, Hiramatsu Y, et al. Up-regulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis. Cancer Res\u20082006; 66: 11623\u201331.","DOI":"10.1158\/0008-5472.CAN-06-2629"},{"key":"2022061623242624600_B50","doi-asserted-by":"crossref","unstructured":"Chiarle R, Pagano M, Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res\u20082001; 3: 91\u20134.","DOI":"10.1186\/bcr277"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/17\/8032\/2573322\/8032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/17\/8032\/2573322\/8032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:35:50Z","timestamp":1655422550000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/17\/8032\/533494\/Genetic-Screening-Reveals-an-Essential-Role-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,1]]},"references-count":50,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2007,9,5]]},"published-print":{"date-parts":[[2007,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-0083","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22368689.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368689","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6496073.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6496073","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,1]]}}}